VEGF therapy in heart disease: for better or for worse?
Springer
Matthew L
ML
D002986:Clinical Trials as Topic; D016228:Endothelial Growth Factors / Q000009:adverse effects / Q000627:therapeutic use*; D006331:Heart Diseases / Q000188:drug therapy*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D008222:Lymphokines / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors